NASDAQ:ORGO Organogenesis (ORGO) Stock Price, News & Analysis $2.48 +0.12 (+5.08%) Closing price 04:00 PM EasternExtended Trading$2.52 +0.04 (+1.61%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Organogenesis Stock (NASDAQ:ORGO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Organogenesis alerts:Sign Up Key Stats Today's Range$2.35▼$2.4850-Day Range$2.24▼$2.7052-Week Range$2.04▼$7.08Volume647,893 shsAverage Volume697,992 shsMarket Capitalization$319.13 millionP/E RatioN/ADividend YieldN/APrice Target$5.75Consensus RatingHold Company Overview Organogenesis Inc. operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers. Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures. These products are supported by clinical data demonstrating efficacy in accelerating wound closure and improving patient outcomes in both inpatient and outpatient settings. Headquartered in Canton, Massachusetts, Organogenesis maintains manufacturing and distribution capabilities in North America with a network of clinical and commercial operations aimed at expanding access to advanced wound care and regenerative therapies. The company continues to invest in research and development to broaden its product pipeline and pursue collaborations that enhance its position in the global regenerative medicine market.AI Generated. May Contain Errors. Read More Organogenesis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreORGO MarketRank™: Organogenesis scored higher than 36% of companies evaluated by MarketBeat, and ranked 633rd out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingOrganogenesis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialOrganogenesis has a consensus price target of $5.75, representing about 131.9% upside from its current price of $2.48.Amount of Analyst CoverageOrganogenesis has only been the subject of 3 research reports in the past 90 days.Read more about Organogenesis' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Organogenesis is -13.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Organogenesis is -13.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrganogenesis has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Organogenesis' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.75% of the float of Organogenesis has been sold short.Short Interest Ratio / Days to CoverOrganogenesis has a short interest ratio ("days to cover") of 15.65, which indicates bearish sentiment.Change versus previous monthShort interest in Organogenesis has recently decreased by 7.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOrganogenesis does not currently pay a dividend.Dividend GrowthOrganogenesis does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Organogenesis this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ORGO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Organogenesis to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Organogenesis insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Organogenesis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions49.57% of the stock of Organogenesis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Organogenesis' insider trading history. Receive ORGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORGO Stock News HeadlinesOrganogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee OsteoarthritisJuly 6 at 4:05 PM | globenewswire.comOrganogenesis Stockholders Reelect Board and Approve Governance ItemsJune 16, 2026 | tipranks.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.July 6 at 1:00 AM | Porter & Company (Ad)Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster OverlookedJune 15, 2026 | seekingalpha.comOrganogenesis Earnings Call: Deep Pain, Long RoadJune 7, 2026 | theglobeandmail.comTruist Securities initiates coverage of Organogenesis Holdings (ORGO) with hold recommendationMay 29, 2026 | msn.comIs Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 UpdateMay 22, 2026 | finance.yahoo.comIs Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 UpdateMay 20, 2026 | insidermonkey.comSee More Headlines ORGO Stock Analysis - Frequently Asked Questions How have ORGO shares performed this year? Organogenesis' stock was trading at $5.18 at the beginning of 2026. Since then, ORGO shares have decreased by 52.1% and is now trading at $2.48. How were Organogenesis' earnings last quarter? Organogenesis (NASDAQ:ORGO) announced its earnings results on Thursday, May, 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by $0.08. The firm earned $37.23 million during the quarter, compared to analyst estimates of $43.26 million. Organogenesis had a negative net margin of 0.84% and a positive trailing twelve-month return on equity of 9.63%. Read the conference call transcript. How do I buy shares of Organogenesis? Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Organogenesis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organogenesis investors own include NVIDIA (NVDA), Financial Select Sector SPDR Fund (XLF), Enterprise Products Partners (EPD), Advanced Micro Devices (AMD), Energy Transfer (ET), Moderna (MRNA) and Company Calendar Last Earnings5/07/2026Today7/06/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ORGO's financial health is in the Red zone, according to TradeSmith. ORGO has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORGO CIK1661181 Weborganogenesis.com Phone(781) 575-0775FaxN/AEmployees950Year Founded1985Price Target and Rating Average Price Target for Organogenesis$5.75 High Price Target$9.00 Low Price Target$3.00 Potential Upside/Downside+131.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$37.03 million Net Margins-0.84% Pretax Margin0.83% Return on Equity9.63% Return on Assets4.76% Debt Debt-to-Equity Ratio0.05 Current Ratio3.53 Quick Ratio3.16 Sales & Book Value Annual Sales$564.17 million Price / Sales0.57 Cash Flow$0.68 per share Price / Cash Flow3.65 Book Value$2.36 per share Price / Book1.05Miscellaneous Outstanding Shares128,680,000Free Float104,484,000Market Cap$319.13 million OptionableOptionable Beta1.33 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ORGO) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Tech forecaster George Gilder - who identified Amazon when it was still just an online bookstore and predicted...Eagle Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredElon’s New Currency (BUY NOW)Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...InvestorPlace | SponsoredMove your money (NOT into the next AI IPO)While headlines focus on AI IPOs, the world's largest investors are moving capital into one asset at the faste...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
